Inventor
Mei-chang Kuo
Inventor
Palo Alto, CA, US
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07KPeptides16%
C12NMicroorganisms or enzymes8%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
A61MDevices for introducing media into, or onto, the body7%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
Y10TTechnical subjects covered by former us classification2%
B65DContainers for storage or transport of articles or materials, e.g. bags, barrels, bottles, boxes, cans, cartons, crates, drums, jars, tanks, hoppers, forwarding containers1%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
10,961,336Method of functionalizing fluoropolymers with acidic side chains exhibiting improved properties, the fluoropolymers thereof, and methods of using202110,842,951Liquid insulin formulations and methods relating thereto202010,744,282Preservative free insulin formulations202010,561,608Dry powder Vancomycin compositions and associated methods202010,525,214Preservative-free single dose inhaler system202010,420,722Dry powder vancomycin compositions and associated methods201910,076,613Preservative free insulin formulations20189,572,774'Dry powder vancomycin compositions and associated methods'20179,545,488'Preservative-free single dose inhaler systems'20179,447,154'Nucleic acids encoding a house dust mite allergen, Der p III, and uses thereof'20169,180,261'Preservative free insulin formulations and systems and methods for aerosolizing'20159,004,061'Preservative-free single dose inhaler systems'20158,950,394'Preservative-free single dose inhaler systems'20158,900,555'Insulin derivative formulations for pulmonary delivery'20148,777,011'Capsule package with moisture barrier'20148,580,919'Polymer conjugates of GLP-1'20138,540,999'Allergenic proteins and peptides from Japanese cedar pollen'20138,501,240'Compositions comprising an active agent'20138,293,869'Polymer conjugates of GLP-1'20128,287,875'Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor'20128,067,431'Chemically modified small molecules'20117,666,429'Nucleic acids encoding a house dust mite allergen Der P III, and uses therefor'20107,482,024'Compositions comprising an active agent'20097,482,008'Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor'20097,288,256'T cell epitopes of the major allergens from dermatophagoides (house dust mite)'20077,211,408'Recombitope peptides'20077,112,333'T cell epitopes of ryegrass pollen allergen'20066,982,326'Allergenic proteins and peptides from Japanese cedar pollen'20066,890,518'Compositions of chemically modified insulin'20056,838,076'Pulmonary administration of chemically modified insulin'20056,835,372'Compositions comprising an active agent'20046,752,991'Nucleic acids encoding a house dust mite allergen Der p III, and uses therefor'20046,589,560'Stable glassy state powder formulations'20036,518,239'Dry powder compositions having improved dispersivity'20036,335,020'Allergenic peptides from ragweed pollen'20026,335,019'Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen'20026,309,671'Stable glassy state powder formulations'20016,268,491'T cell epitopes of the major allergens from dermatophagoides (house dust mite)'20016,258,341'Stable glassy state powder formulations'20016,180,771'Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor'20016,090,386'T cell peptides of the CRX JII allergen'20006,048,962'Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor'20006,019,972'Peptides of human T cell reactive feline protein (TRFP)'20005,968,526'T cell epitopes of the major allergens from Dermatophagoides (house dust mite)'19995,820,862'T cell epitopes of the major allergens from dermatophagoides (house dust mite)'19985,776,761'Nucleic acids encoding allergenic proteins from ragweed'19985,710,126'T cell epitopes of ryegrass pollen allergen'19985,698,204'Recombinant allergenic proteins from ragweed pollen'19975,547,669'Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I'19965,328,991'Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes'1994Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1994–2006Patents assigned to IMMULOGIC PHARMA CORP (13)· patent assignee history
1994–2016Based in Winchester, MA, US· patent location history
2000–2020Based in Palo Alto, CA, US· patent location history
2003–2014Patents assigned to NEKTAR THERAPEUTICS (9)· patent assignee history
2007–2016Patents assigned to MERCK PATENT GMBH (7)· patent assignee history
2011–2016Patents assigned to KUO MEI-CHANG (11)· patent assignee history
2015–2020Patents assigned to DANCE BIOPHARM INC (6)· patent assignee history
2021Based in Denver, CO, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IMMULOGIC PHARMA CORP | 13 | 1994–2006 |
| KUO MEI-CHANGself | 11 | 2011–2016 |
| NEKTAR THERAPEUTICS | 9 | 2003–2014 |
| MERCK PATENT GMBH | 7 | 2007–2016 |
| DANCE BIOPHARM INC | 6 | 2015–2020 |
Locations
| Location | Patents | Span |
|---|---|---|
| Palo Alto, California, US | 28 | 2000–2020 |
| Winchester, Massachusetts, US | 21 | 1994–2016 |
| Denver, CO, US | 1 | 2021 |